|本期目录/Table of Contents|

[1]刘杰,欧国春,曾静,等.不同强度他汀类药物对中国人群冠状动脉粥样硬化性心脏病疗效及安全性的系统评价[J].国际心血管病杂志,2018,02:117-122.
　LIU Jie,OU Guochun,ZENG Jing,et al.Efficacy and safety of different intensity statin therapy on coronary heart disease in Chinese population: a systematic review and meta-analysis[J].International Journal of Cardiovascular Disease,2018,02:117-122.
点击复制

不同强度他汀类药物对中国人群冠状动脉粥样硬化性心脏病疗效及安全性的系统评价

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2018年02期
页码:
117-122
栏目:
临床研究
出版日期:
2018-03-25

文章信息/Info

Title:
Efficacy and safety of different intensity statin therapy on coronary heart disease in Chinese population: a systematic review and meta-analysis
作者:
刘杰; 欧国春; 曾静; 梁豪; 胡厚祥
637000 南充,川北医学院附属医院心内科(刘杰,曾静,梁豪,胡厚祥),呼吸内科(欧国春)
Author(s):
LIU Jie1;  OU Guochun2; ZENG Jing1; LIANG Hao1; HU Houxiang1.
1. Department of Cardiology; 2. Department of Respiratory Medicine, The Affiliated Hospital of North Sichuan Medical College, Sichuan 637000, China
关键词:
他汀类药物;  冠状动脉粥样硬化性心脏病;  中国人;  meta分析;  系统评价
Keywords:
Statins;  Coronary heart disease;  Systematic review
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2018.02.014
文献标识码:
-
摘要:
目的:评价不同强度他汀类药物对中国人群冠状动脉粥样硬化性心脏病(冠心病)的疗效及安全性。方法:计算机检索PubMed、Embase、Web of Science、中国生物医学文献数据库(CBM)、万方医学网数据库、中国知网学术文献总库(CNKI)、中文科技期刊数据库(VIP)等,并辅以手工检索。采用RevMan 5.3、STATA 14.0对符合纳入标准的18篇文献进行数据分析。结果:(1)与中等强度他汀相比,高强度他汀的非致命性心肌梗死(OR=0.43,P=0.000 7)、死亡(OR=0.43,P=0.001)和总终点事件(OR=0.56,P<0.000 1)的发生率均较低,总胆固醇(TC)水平(MD=-0.44,P<0.000 01)和低密度脂蛋白胆固醇(LDL-C)水平(MD=-0.35,P<0.000 01)也较低,但不良反应(OR=1.34,P=0.98)和脑卒中(OR=0.66,P=0.11)的发生率无统计学差异;(2)使用中等强度他汀与低强度他汀的患者,死亡率的差异无统计学意义(OR=0.54,P=0.44)。结论:与中强度他汀相比,高强度他汀降低TC和LDL-C水平的效果更明显,并能减少非致命性心肌梗死、死亡和总终点事件的发生率,且不增加不良反应; 但不降低脑卒中的发生率。
Abstract:
Objective:To systematically review the therapeutic efficacy and safety of different intensity statin in the treatment of coronary heart disease(CHD)among the Chinese population.Methods:Such databases as PubMed, Embase, Web of Science, CBM, CNKI, VIP, WanFang Data were used by computer retrieval. References to relevant literature were also screened by manual retrieval. 18 literatures were finally included and the data were analyzed by RevMan 5.3 and STATA 14.0.Results:(1)Compared with moderate intensity statin, although high intensity statin therapy had no superior effect on reduction of stroke(OR=0.66, P=0.11), it possessed significant reducing effects on nonfatal myocardial infarction(OR=0.43, P=0.000 7), death(OR=0.43, P=0.001), total end point event(OR=0.56, P<0.000 1), total cholesterol(TC)levels(MD=-0.44, P<0.000 01)and low density lipoprotein cholesterol(LDL-C)levels(MD=-0.35, P< 0.000 01)with no increase in adverse reactions(OR=1.34, P=0.98).(2)There was no statistically significant difference between the deaths rate of moderate intensity statin group and that of low intensity statin(OR=0.54, P=0.44).Conclusions:Compared with moderate intensity statin, high intensity statin therapy for CHD could effectively decrease the incidences of nonfatal myocardial infarction, death, total end point event, TC levels and LDL-C levels with no increased risk of side effects in Chinese population. However, it showed no reducing effect on the risk of stroke.

参考文献/References

[1] European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, et al. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European society of cardiology(ESC)and the European atherosclerosis society(EAS)[J]. Eur Heart J, 2011, 32(14):1769-1818.
[2] Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults a report of the American college of cardiology/American heart association task force on practice guidelines[J]. J Am Coll Cardiol, 2014, 63(25 B):2889-2934.
[3] Cannon CP, Braunwald E, McCabe CH,et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes [J]. N Engl J Med, 2006, 350(15):1495-1504.
[4] Larosa JC, Grundy SM, Waters DD. Intensive lipid lowering with atorvastatin in patients with stable coronary disease[J]. N Engl J Med, 2005, 352(14):1425-1435.
[5] Zhao SP, Yu BL, Peng DQ, et al. The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: results of the CHILLAS trial[J]. Atherosclerosis, 2014, 233(2):707-712.
[6] 刘西方. 不同剂量阿托伐他汀治疗急性冠脉综合征的疗效及安全性观察[J]. 基层医学论坛, 2016, 20(12):1612-1613.
[7] 余阳阳, 白锋, 余静, 等. 阿托伐他汀强化疗法治疗PCI术后急性冠脉综合征患者的效果观察[J]. 山东医药, 2015, 55(37):73-75.
[8] 裴宜斌, 冷利华, 黄文胜. 强化瑞舒伐他汀钙对急性冠脉综合征患者血清C反应蛋白及预后的影响[J]. 海军医学杂志, 2015, 36(6):548-550.
[9] 陈卓, 吕美平. 不同剂量阿托伐他汀治疗急性冠脉综合征80例临床分析[J].海南医学, 2013, 24(15): 2202-2204.
[10] 孙元芬, 胡小燕, 王海滨, 等. 强化降脂治疗对急性冠脉综合征合并糖尿病老年患者炎症因子和预后的影响[J]. 中国医刊, 2013, 48(2):33-35.
[11] 郭胜. 强化他汀治疗对不稳定心绞痛患者预后影响[J].中国医疗前沿, 2013, 8(24):12.
[12] 白智峰. 不同剂量阿托伐他汀对冠心病经皮冠状动脉介入术后患者血脂和心脏缺血事件的影响[J]. 中国基层医药, 2013, 20(16):2413-2415.
[13] 李京倡, 张晓. 早期阿托伐他汀强化治疗对急性冠脉综合征患者PCI术后预后的影响[J]. 中国现代医学杂志, 2012, 22(31):61-64.
[14] 谢进, 李欣, 许臣洪, 等. PCI围术期阿托伐他汀强化治疗对冠心病患者术后再狭窄的影响[J]. 四川医学, 2012, 33(6):989-991.
[15] 徐桂华, 夏辉. 不同剂量阿托伐他汀治疗急性冠脉综合征临床疗效对比分析[J]. 安徽医学, 2012, 33(8):1016-1018.
[16] 黄仲略, 谢彬, 杨国康, 等. 不同剂量普伐他汀治疗急性冠脉综合症的临床效果分析[J]. 数理医药学杂志, 2011, 24(1):48-50.
[17] 潘朝锌, 何贵新. 大剂量阿托伐他汀治疗急性冠脉综合征的疗效及安全性[J]. 心血管康复医学杂志, 2010, 19(3):284-287.
[18] 高红伟. 不稳定型心绞痛早期不同剂量辛伐他汀疗效观察[J]. 临床医学, 2009, 29(3):60-62.
[19] 汤成春, 马根山, 冯毅, 等. 不同剂量阿托伐他汀早期应用治疗急性冠脉综合征的疗效观察[J]. 现代医学, 2008,36(6):410-412.
[20] 邓少雄, 郭南鸥. 不同剂量阿托伐他汀对急性心肌梗死PCI术后的作用[J]. 中国心血管病研究, 2008, 6(10):744-745.
[21] Liu Z, Joerg H, Hao H, et al. Efficacy of high-intensity atorvastatin for Asian patients undergoing percutaneous coronary intervention[J]. Ann Pharmacother, 2016, 50(9): 725-733.
[22] Huang B, Cheng Y, Xie Q, et al. Effect of 40 mg versus 10 mg of atorvastatin on oxidized low-density lipoprotein,high-sensitivity C-reactive protein,circulating endothelial-derived microparticles,and endothelial progenitor cells in patients with ischemic cardiomyopathy[J]. Clin Cardiol, 2012, 35(2):125-130.

备注/Memo

备注/Memo:
基金项目:国家自然科学基金(81600232)
通信作者:胡厚祥,Email:hhxiang17@163.com
更新日期/Last Update: 2018-04-20